Literature DB >> 16243151

Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge.

Wing-Yan Au1, Yok-Lam Kwong.   

Abstract

In 44 patients treated with arsenic trioxide (As2(O3)) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2(O3).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16243151     DOI： 10.1016/j.jaad.2005.07.030

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  8 in total

1.  Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.

Authors:  Mark D Sides; Gregory J Block; Bin Shan; Kyle C Esteves; Zhen Lin; Erik K Flemington; Joseph A Lasky
Journal:  Virology       Date:  2011-05-24       Impact factor: 3.616

2.  Severe varicella infection occurring after herpes zoster reactivation in a patient with AIDS.

Authors:  Catherine W M Ong; Brenda S P Ang; Cheng Chuan Lee
Journal:  BMJ Case Rep       Date:  2009-04-07

3.  Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.

Authors:  Angela M Mitchell; Chengwen Li; R Jude Samulski
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

4.  Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.

Authors:  Mike Reichelt; Li Wang; Marvin Sommer; John Perrino; Adel M Nour; Nandini Sen; Armin Baiker; Leigh Zerboni; Ann M Arvin
Journal:  PLoS Pathog       Date:  2011-02-03       Impact factor: 6.823

Review 5.  Arsenic toxicology: translating between experimental models and human pathology.

Authors:  J Christopher States; Aaron Barchowsky; Iain L Cartwright; John F Reichard; Bernard W Futscher; R Clark Lantz
Journal:  Environ Health Perspect       Date:  2011-06-17       Impact factor: 9.031

6.  Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.

Authors:  Jacob L Glass; Andriy Derkach; Patrick Hilden; Amber King; Susan K Seo; Katya Ahr; Ashwin Kishtagari; Ross L Levine; Martin S Tallman; Dan Douer
Journal:  Leuk Res       Date:  2021-03-31       Impact factor: 3.715

7.  Arsenic exposure and prevalence of the varicella zoster virus in the United States: NHANES (2003-2004 and 2009-2010).

Authors:  Andres Cardenas; Ellen Smit; E Andres Houseman; Nancy I Kerkvliet; Jeffrey W Bethel; Molly L Kile
Journal:  Environ Health Perspect       Date:  2015-01-30       Impact factor: 9.031

Review 8.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.